Investor Relations


48-49 Russell Square, London, WC1B 4JP UK

T: +44 (0)203 0084416


Shareholders Information 2011

Please see the folder "General Meeting Documentation" under the Investor Relations section for information on the forthcoming General Meetings and all documentation in relation to AGM's from January 2011 onwards.

ValiRx Plc's or 'The Company' house broker, Hybridan LLP, will from time to time publish research notes from this page.  Any opinions, estimates or forecasts regarding The Company's performance made by the brokers are theirs alone and do not represent opinions, forecasts or predictions of The Company or its Management.  By distributing the information below The Company does not imply its endorsement of or concurrence with such information.    

Please click here to view ValiRx Plc's Corporate Presentation.

ValiRx Plc - Latest News and Video Release - 18 May 2011:-

Satu Vainikka, from Valirx, talks about the unlimited potential of

"Dr Satu Vainikka, CEO at Valirx (LON:VAL), tells Proactive Investors
that there is tremendous potential for its GeneICE programme Satu
believes that the recently raised £3.3mln will see Valirx through to
pre-clinical studies at which point it is likely that a commercial joint
venture partner will be found within the sector."

Proactiveinvestors UK:

You will also find this published on:

Google News:

Google Finance:

News Now:

One News Page:


Moreover Technologies:



You will also shortly find this news disseminated across our social
networking sites here:



Seeking Alpha:

Word Press: